SEC Form 4 · accession 0001209191-18-001000

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP GMDA, CMO

Period of report

Jan 2, 2018

Accepted (ET)

Jan 3, 2018 · 4:56 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jan 2, 2018	M	3,438	$73.51	A	57,862	D
Common Stock^F2,F3	Jan 2, 2018	S	300	$149.65	D	57,562	D
Common Stock^F3,F4	Jan 2, 2018	S	675	$150.87	D	56,887	D
Common Stock^F3,F5	Jan 2, 2018	S	1,600	$152.06	D	55,287	D
Common Stock^F3,F6	Jan 2, 2018	S	863	$152.80	D	54,424	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$73.51	Jan 2, 2018	M	3,438	D	—	Jan 1, 2024	Common Stock	3,438	0	D

F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $149.65 (range $149.41 to $149.92).
F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $150.87 (range $150.53 to $151.50).
F5Open market sales reported on this line occurred at a weighted average price of $152.06 (range $151.70 to $152.69).
F6Open market sales reported on this line occurred at a weighted average price of $152.80 (range $152.70 to $153.03).
F7Fully vested.